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Introduction: Major clinical practice guidelines
recommend assessing risk of cardiovascular disease
(CVD) using absolute/global/total CVD risk scores.
However, the effectiveness of using them in clinical
practice, despite publication of numerous
randomised controlled trials (RCTs), is still poorly
understood. To summarise and analyse current
knowledge in this field, we will carry out an overview
of existing systematic reviews (SRs). The objective
of this overview will be to assess the effect of using
cardiovascular risk scoring in routine risk
assessment in primary prevention of CVD compared
with standard care.
Methods and analysis: We will include SRs and
meta-analyses which take into account RCTs and
quasi-RCTs investigating the effect of using
cardiovascular risk scoring in routine risk
assessment in primary prevention of CVD. SRs will
be retrieved from 4 bibliographical databases and
reference lists of identified reviews. Additionally, the
PROSPERO database will be searched for
unpublished, ongoing or recently completed SRs.
2 reviewers will assess the SRs independently for
eligibility and bias. The data will be extracted to a
special form. Any disagreement will be resolved by
discussion. In case of lack of consensus, a third
author will arbitrate. The overview of SRs will be
reported according to the Preferred Reporting Items
for Systematic Review and Meta-Analyses (PRISMA)
statement.
Ethics and dissemination: Ethics approval is not
required for overview of SRs. We will summarise
evidence concerning whether use of the absolute/
global/total CVD risk scoring tools in primary
prevention of CVD is effective and supported with
scientific data or not. If we face unsatisfactory
confirmation, we will highlight a need for further
research and advice on how to plan such a study. We
will submit the results of our study for peer-review
publication in a journal indexed in the international
bibliographic database of biomedical information.
INTRODUCTION
Cardiovascular disease (CVD) is nowadays
the leading cause of mortality, morbidity and
disability worldwide.1 2 Well-established, modi-
fiable CVD risk factors are: elevated blood
pressure, hypercholesterolaemia, diabetes,
obesity, lack of physical activity, inappropriate
diet, excessive alcohol intake and smoking.
Understanding CVD risk factors makes pre-
vention possible. Risk factor modification can
reduce the number of premature deaths as
well as other clinical events, both in people
with confirmed CVD (secondary prevention)
and people without established CVD, who are
at high cardiovascular (CV) risk (primary
prevention).
The Framingham Heart Study was the first
well-constructed observational study to inves-
tigate CV risk factors.3 The first major find-
ings were reported in 1957,4 and it was
shown that hypertension (HTN) increases
coronary heart disease (CHD) incidence.
The breakthrough in understanding CHD
risk came with an article by Kannel et al5 in
1961, when the term ‘factors of risk’ was
Strengths and limitations of this study
▪ We anticipate our study to be the first and
largest overview of systematic reviews in this
area.
▪ A robust search strategy has been prepared by
an experienced librarian.
▪ Electronic search strategy is limited to four main
international bibliographic databases and the
English language literature only.
▪ This article is a protocol of the overview of sys-
tematic reviews. The results of the overview will
be published in a different article.
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used and it was proved that HTN, hypercholesterolaemia
and other risk factors ‘precede the development of overt
CHD in humans and are associated with increased risk
of development of CHD’.
After individual risk factors of CVD were identified in
the Framingham Heart Study,3 the new concept of the
absolute/global/total CVD risk was taken into consider-
ation. By definition, absolute CVD risk is the actual risk
of developing this disease by the defined population in
a defined period of time (mostly 10 or 5 years).6 The
absolute/global/total CVD risk is calculated by using a
combination of present major risk factors. To individual-
ise the absolute/global/total risk for an individual
patient, risk scores, which use function equations based
on multiple risk factors, are in use.7
The first multivariate analysis on the Framingham
Cohort was published by Truett et al8 in 1967.
After the success of the Framingham Heart Study,
other risk scores were created in the USA, European
countries and other parts the world, and their numbers
grew rapidly. In 2008, Beswick et al9 identified 110 prog-
nostic models or risk scoring methods with potential use
in targeting primary prevention of CVD. The most well-
known and widely used are: Systematic COronary Risk
Evaluation (SCORE) algorithm,10 QRISK11 and
QRISK2,12 the WHO risk score, and American College
of Cardiology/American Heart Association (ACC/AHA)
2013 Pooled Cohort risk equations.13
A research project for the development of the
European CVD risk-prediction model (SCORE project)
was initiated by the Working Group on Epidemiology and
Prevention of the European Society of Cardiology (ESC)
in 1994. To ensure best applicability in the European
region, the SCORE project gathered a pool of data sets
from 12 European cohort studies. The SCORE model
predicts the 10-year risk of CV mortality in individuals
(aged 40–65) without pre-existing CVD. The total CVD
risk is calculated using individual’s gender, smoking
status, age, blood pressure and total cholesterol level
(or total cholesterol/high-density lipoprotein choles-
terol ratio).10 Since its publication date, many countries
have developed specific versions of the SCORE.14–17
Major clinical practice guidelines (Canadian
Cardiovascular Society (CCS),18 European Society of
Cardiology/European Society of Hypertension (ESC/
ESH),19 ACC/AHA,20 Joint British Societies (JBS3)21) rec-
ommend assessing risk of CVD using the absolute/
global/total CVD risk scores. It was confirmed that use of
risk scores increases the accuracy of prediction of CVD
events and may guide management decisions in primary
prevention. Unfortunately, only a few global CVD risk
scores were externally validated. Validation is an important
feature which is used to evaluate the performance of risk
score models and to verify, whether they can be applied
outside the settings in which they were developed.
The effectiveness of using absolute/global/total risk
scores can be proved by randomised control trials
(RCTs). Some RCTs were published over the past two
decades. The research community tried to summarise
existing evidence in this field, which resulted in the
publication of a few systematic reviews (SRs).
In 2006, Brindle et al22 published a well-known work in
which they tried to assess the impact of CVD risk predic-
tion on clinical outcomes. However, they did not find a
strong correlation. Since then, several papers have been
published23–25 with similar conclusions. Moreover, in
2015, two SR protocols focusing on the influence of
using CVD risk scoring on care and outcomes were pub-
lished. The first, by Karmali et al26 was published in the
Cochrane Library. The second, by Tomasik et al,27 is
available online.
Despite numerous publications, there are still
unsolved issues. One of them is whether using the abso-
lute/global/total CVD risk scoring (total risk assessment
—TRA) is clinically effective when outcomes important
for patients are taken into account (eg, mortality, CV
events). Additionally, there are not much data about the
adverse effects of TRA. The absence of information does
not mean that the procedure is completely safe.
Even though, TRA for CVD has high external validity
since it appropriately predicts CV events, it does not
mean that beneficial clinical effects will be obtained
when using it.
The first and main barrier limiting the knowledge in
this area is, in fact, that there were only a few experimen-
tal studies measuring the efficacy of using TRA tools. On
the contrary, however, quite a lot of studies referring to
calibration and discrimination were published. The
second barrier is that in some studies the surrogate end
points were used to show effectiveness. In the literature
we may find examples which demonstrate a benefit from
a particular intervention when surrogate markers were
used, but later, a repeated study regarding hard out-
comes did not demonstrate a benefit or even showed
harm.28
In this connection, the effectiveness of using global
CVD risk scores in clinical practice is still poorly under-
stood. On the one hand it can be beneficial and
improve health (eg, identifying high-risk individuals who
will most likely benefit from risk factor management).
On the other hand, it may be harmful (undertreatment
of youngsters or overtreatment of the elderly) and
misuse resources (eg, time and cost of laboratory tests).
Objectives
We will carry out an overview of existing SRs. Such an
overview is suggested as a logical and appropriate step
for comparing and contrasting separate reviews. Our
objectives in this study are: (1) to analyse and summarise
the best current evidence for the effectiveness of using
CV risk scoring in routine risk assessment in primary
prevention of CVDs compared with standard care; (2) to
assess whether use of a particular risk score followed by
structured or unstructured intervention is more effective
than another risk score in improving patient outcomes;
and (3) to discuss how our findings can be used to
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guide clinicians, policymakers and provide a guideline
for authors in future.
METHODS/DESIGN
Our research methods will follow the ‘Preferred
Reporting Items for Systematic Review and Meta-Analysis
Protocols’ (PRISMA-P).29 30 The PRISMA-P checklist is
presented in an online supplementary appendix 1.
Eligibility criteria
Studies will be selected according to the criteria defined
below.
Studies
We will include SRs and meta-analyses which take into
account RCTs and quasi-RCTs investigating the effect of
using CV risk scoring in routine risk assessment in
primary prevention of CVD. If SRs also take into
account other studies (ie, observational), they will be
included as well. We will include both SRs reported as
full text as well as any published as abstract only.
Included reviews have to describe a systematic search
strategy.
Participants
Participants will be adults (19 years of age and over) free
of clinical CVD. They may have different CVD risk
factors or other diseases including diabetes and chronic
kidney disease.
Interventions
Intervention: CVD risk assessment with use of the abso-
lute/global/total CVD risk scoring (TRA), performed by
physicians or other healthcare professionals.
Comparator: Standard care with no use of the global
CVD risk scoring provided by a physician or healthcare
professional. Treatment and lifestyle recommendations
in comparative intervention should be based on other
methods, for example, assessment of only one particular
risk factor, counting the number of risk factors or no
CVD risk assessment at all (treatment based completely
on physicians’ ‘gut feeling’).
Outcomes
Primary outcomes: (1) CVD death, (2) fatal and non-fatal
CV event, (3) adverse events—(any physical, psycho-
logical or social events).
Secondary outcomes: (1) All-cause mortality, (2) change in
predicted global CVD risk, (3) change in patient CVD
risk factors—change in blood pressure, cholesterol level,
smoking, exercise, diet, alcohol consumption and
obesity, (4) prescription of risk-reducing drugs according
to prevailing guidelines (aspirin, antihypertensives,
lipid-lowering agents), (5) pharmacotherapy without or
against current clinical guideline recommendations.
Adverse events mentioned as primary outcomes could
be as follows: (1) physical—for example, HTN or
dyslipidaemia complications in young patients who were
excluded from pharmacotherapy due to low CVD risk
score; (2) psychological—for example, anxiety, depres-
sion, stress caused by diagnosis and being labelled as
‘chronically ill’; (3) social—for example, costs and add-
itional time spent on unnecessary consultations, roles
changing in family or society.
Setting
Only studies performed in a primary care setting will be
eligible.
Information sources




▸ CENTRAL (Cochrane Central Register of Controlled
Trials);
▸ SCOPUS.
We will search all databases from 1990 to the present
(only a very small number of SRs were conducted before
that time).31 32 The search will be limited to the English
language literature. This search will be supplemented by
a search for unpublished, ongoing or recently com-
pleted SRs in PROSPERO. In addition, we will also hand
search the reference lists of all included SRs.
Search strategy
The preliminary search strategy for MEDLINE (Ovid) is
presented in online supplementary appendix 2. Search
strategy was based on that presented in one of the
authors’ previous studies.27 Search terms containing
names of different CVD risk scores were adopted from
the work of Beswick et al.9 Search strategy for MEDLINE
will be adapted for use in other databases.
STUDY RECORDS
Data management
All records identified will be uploaded or manually
entered into Mendeley V.1.16.3 (Elsevier).
Selection process
After initial duplicate removal, titles and abstracts from
the searches will be independently screened by two
authors (KS, JK). Full-text articles will be retrieved for all
potentially includable SRs or SR protocols. Any disagree-
ments will be resolved through discussion. In case of
lack of consensus, a third author (TT) will arbitrate.
If any ongoing or unpublished study is identified, we will
contact the corresponding author for information about
whether any preliminary data may be included in our
overview.
Data collection process
The methodology for data extraction and analysis will be
based on the guidance from Preferred Reporting Items
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for Systematic Reviews and Meta-Analyses (PRISMA)
statement33 and the Cochrane Handbook of Systematic
Reviews of Interventions.34
Two authors (KS, JK) will independently extract
outcome data from each included review using a prede-
fined data extraction form. This form will be developed
and will be piloted using the first three eligible reviews
and amended where required. Disagreements during
the data extraction process will be resolved through dis-
cussion. In case of lack of consensus, a third author
(TT) will arbitrate.
Data items
We will extract the following information: (1) administra-
tive and bibliographic data (author names and institu-
tions, journal title, publication year, role of study
sponsors and funding sources, reported conflicts of
interest); (2) the characteristics of each review (primary
research questions and all outcomes for which data were
sought, eligibility criteria used, number and biblio-
graphic data of primary studies included, the applied
search strategy including search periods, study selection
methods and applied limitations); (3) methodological
details and results of meta-bias assessments (if con-
ducted); (4) reported limitations of each review; (5)
results and conclusions of the review.
Additionally, we will extract the following information:
(1) outcomes reported in a particular SR, which were
recognised by the authors as evidence of the effective-
ness of TRA, (2) reported effect of TRA in different
populations, and (3) reported effect of different TRA in
the same population.
We will also describe how the fatal and non-fatal CV
events were defined in each SR.
If a meta-analysis has been conducted, we will extract
both its results and all relevant methodological aspects
(eg, types and unity of data, effect measured, heterogen-
eity, sensitivity analysis).
Outcomes and prioritisation
All outcomes, for which data will be sought, are listed in
the ‘outcomes’ subsection in the ‘eligibility criteria’
section of this protocol. We assume that primary out-
comes chosen for this study are most important because:
(1) they are objective and clinically relevant; and (2)
they include beneficial and adverse effects. We would
like to emphasise that in our study, adverse events are
also considered as ‘main’ outcomes, because of their
importance in everyday practice. Although secondary
outcomes are less important, we are convinced that they
will help to understand the influence and outcomes of
using the absolute/global/total CVD risk scoring in
general practice and give information for researchers
planning further studies.
Risk of bias in included SRs
Currently there is no gold standard for the assessment
of risk of bias for each SR included in an overview.34 35
Two reviewers (KS, TT) will independently appraise risk
of bias of the included SRs using validated AMSTAR
(assessment of multiple SRs) checklist, which is most
commonly used to assess the quality of SRs included in
overviews.35 We will score each SR with a maximum of
11 points. Disagreements will be resolved through dis-
cussion. In case of lack of consensus, a third author
( JK) will arbitrate. Each SR will be assigned to one of
three quality levels (0–3 points—low quality, 4–7 points
—medium quality and 8–11 points—high quality).36 37
DATA
Data synthesis
Presentation of results of our study will align guidelines
from the PRISMA statement33 and the Cochrane
Handbook of Systematic Reviews of Interventions.34 A
PRISMA flow diagram will be used to summarise search
results. Data will be presented as a narrative synthesis. A
series of summary tables and figures will supplement
textual commentary to enhance the clarity of our report-
ing.38 We will also report outcomes of interest for which
no reviews were found. We will not conduct a meta-
analysis of meta-analyses. Even when two or more suitable
meta-analyses are found, we do not plan to do that
because of the risk of introducing bias. According to
Smith et al38 and Pieper et al39 such undesired bias can be
easily incorporated (due to giving excessive statistical
power to primary studies included in more the one SR)
when performing meta-analysis in review of SRs.
Moreover, the same authors highlight that planning such
meta-analysis requires careful consideration and there is
no well-established quantification method in this field.
Risk of bias across SRs
To assess selective outcome reporting within SRs, we will
compare outcomes which were planned to be assessed in
the SR protocols (or, if unavailable, in the methods
section of the published report of SR) and others reported
in the results section of the published report of SR.
To minimise publication bias, we would like to identify
all relevant unpublished or ongoing SRs by searching
the PROSPERO database. If we succeed, we will contact
the corresponding author and ask for preliminary data
that can be included in our overview.
To assess the degree of overlap in the inclusion of
primary studies between SRs, the citation matrix will be
generated by one reviewer and checked by a second for
accuracy. It will cross-link SRs (columns) with primary
studies included in SRs (rows). The degree of overlap
will be calculated with use of the corrected cover area in
our citation matrix.39
Confidence in cumulative evidence
To strengthen the body of evidence, in our overview we
will take into account SRs analysing RCTs, quasi-RCTs
and non-experimental prospective trials.
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We will use the assessment of quality of evidence per-
formed by original SR authors. We will appraise the
quality of evidence across the domains of risk of bias,
precision, consistency and publication bias.
DISCUSSION
Our review will be a comprehensive synthesis of the
existing SR literature describing the effectiveness of
using CV risk scoring in routine risk assessment in
primary prevention of CVD. To the best of our knowl-
edge, it will be the first such study in this area.
In the discussion section in the full report of our study,
we plan to include the following subsections, typical for
this type of study: (1) summary of main findings; (2)
strength and limitations; (3) comparison with other
studies and opinions; (4) interpretation of results; (5)
ethical considerations and funding; and (6) conclusion.
We are aware that the methodology of overview of SRs
is less developed than the methodology of SRs.
We strongly believe that results of our study will be
important for medical professionals. They will receive
up-to-date and persuasive evidence, whether use of the
TRA tools in primary prevention of CVD is supported by
scientific data or not. If the legitimacy of using TRA is
proved then that will be additional encouragement for
using this tool in everyday practice by healthcare profes-
sionals in future. Our best intention is also to provide
sufficient data for policymakers, which will help them to
project and conduct CVD primary prevention pro-
grammes in future. We are convinced that our study will
be interesting for researchers. We suspect it will uncover
gaps in our knowledge and therefore reveal areas of
future research. We hope that the results of our study
will improve (non-directly) the health of many patients.
Receiving information about a strong scientific back-
ground of performed CVD risk assessment will boost
patients’ adherence to instructions from the physician
on non-pharmacological or pharmacological therapy.
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